TMC
OREX

Trellus Management Company’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Trellus Management Company’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-6,000
Closed -$127K – 117
2015
Q3 		$127K Buy
+6,000
New +$206K 0.19% 80

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Trellus Management Company's OREX Position: Q4 2015 in Review

Trellus Management Company sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2015, closing a stake of 6,000 shares — an estimated $127K sold.

Trellus Management Company first reported a position in OREX in Q3 2015 and held it in 1 quarter. The position peaked at $127K in Q3 2015. 121 funds tracked by Wall St. Rank hold OREX as of Q4 2015.

  • Trellus Management Company reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Trellus Management Company sold 6,000 Orexigen Therapeutics, Inc. shares in Q4 2015, an estimated $127K.
  • Trellus Management Company first reported a position in Orexigen Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • Trellus Management Company's Orexigen Therapeutics, Inc. position peaked at $127K in Q3 2015.
  • 121 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2015.

Based on Trellus Management Company's 13F filing for Q4 2015, filed 27 Jan 2016.